Nanoparticle injection reprograms NK immune cells to fight cancer and autoimmune disorders

Nanoparticle injection reprograms NK immune cells to fight cancer and autoimmune disorders

Report

by Anne Trafton, Massachusetts Institute of Technology

Report

edited by Sadie Harley, reviewed by Robert Egan

Report

MIT engineers have developed a new way to program natural killer (NK) immune cells to target cancerous T cells or T cells that have become autoreactive, leading to diseases such as lymphoma and autoimmune hepatitis.

Report

Using their new technique, the researchers can reprogram NK cells to target diseased T cells without ever removing the NK cells from the patient's body.

Report

Instead, they use lipid nanoparticles to deliver messenger RNA directly to NK cells.

Report

These mRNA molecules encode proteins that allow the NK cells to seek and destroy the dysfunctional T cells.

Report

"The manufacturing challenges with CAR NK cells are significant.

Report

The idea here is you can deliver a nanoparticle that will modify your own NK cells with a CAR construct and teach them to attack tumor cells," says Daniel Anderson, a professor in MIT's Department of Chemical Engineering and a member of MIT's Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science.

Report

Anderson is the senior author of the study, which appears in Nature Biotechnology.

Report

The paper's lead authors are MIT postdoc Yuang Chen and MIT graduate students Julia Monkovic and Haseeb Mughal.

Report

Koch Institute Professor at MIT, is also an author.

Report

Over the past decade, the U.S. Food and Drug Administration has approved seven new cancer treatments based on engineered T cells called chimeric antigen receptor (CAR) T cells.

Report

Chimeric antigen receptors are proteins that can be embedded into T cells, allowing them to detect a target antigen, such as a cancer protein.

Report

When the target is detected, the T cell becomes activated and destroys the target cell.

Report

This approach has had great success in treating blood cancers, primarily those that originate from B cells, including several types of leukemia, lymphoma and multiple myeloma.

Report

To make CAR T cells, doctors take a blood sample from the patient.

Report

The sample is sent to a lab where the T cells are isolated and then engineered to express the CAR protein.

Report

When enough CAR T cells have been generated, they are shipped back to the hospital and infused into the patient.

Report

In recent years, scientists have begun using a similar strategy to create CAR NK cells.

Report

One potential advantage of CAR NK cells over CAR T cells is that they could be used to kill diseased T cells.

Report

Using CAR T cells to treat T cell diseases often doesn't work well because T cells that are engineered to target T cell proteins may end up killing each other, in addition to the diseased T cells.

Report

That issue doesn't arise when using NK cells to target T cells.

Report

"NK cells can treat these T cell malignancies—not only T cell cancer, but also T cell autoimmune diseases," Chen says.

Report

However, manufacturing large quantities of CAR NK cells poses many of the same difficulties as generating CAR T cells.

Report

To simplify the process, the MIT team wanted to come up with a way to generate CAR NK cells "in vivo"—that is, in the patient's own body, without having to remove any cells.

Report

Currently, there are no FDA-approved CAR NK cell therapies, but many researchers are working on developing them to treat cancer or autoimmune disorders.

Report

To generate these cells, the MIT team designed lipid nanoparticles (LNPs) that can deliver an mRNA payload.

Report

These strands of mRNA encode a CAR that can be targeted to specific cell types.

Report

For example, they could deliver a CAR that targets CD19, a protein found on B cells, or CD3, a protein found on autoreactive T cells.

Report

The particles are coated with antibody fragments that bind to receptors found on the surface of NK cells to ensure they reach the correct targets.

Report

After these particles were infused into mice, the researchers found that they could successfully reprogram about 80% of the targeted NK cells.

Report

The researchers then tested the particles' potential to treat cancer and autoimmune hepatitis, which is caused by autoreactive T cells.

Report

In a mouse model of an aggressive form of melanoma, three of the five mice that received LNPs that reprogrammed their NK cells to target the cancer cells went into complete remission.

Report

The researchers also saw significant tumor destruction when they used the LNPs to treat T cell lymphoma in a humanized mouse model, created when mice receive transfusions of human blood cells, allowing them to transiently generate a human-like immune system.

Report

In these mice, tumors were eradicated after five injections of the reprogramming LNPs.

Report

This result was similar to what the researchers saw when they treated mice with CAR NK cells that were generated using the conventional approach—removing NK cells, reprogramming them and returning them to the mice.

Report